4 drug(s) with this reaction
4,228 total reports
Therapy Non Responder has been reported as an adverse reaction across 4 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 4,228 adverse event reports mention therapy non responder in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with therapy non responder, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have therapy non responder listed in their FDA adverse event reports, sorted by report count:
In addition to therapy non responder, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
4 drug(s) manufactured by Amgen Inc have therapy non responder listed in their FDA adverse event reports: APREMILAST, BLINATUMOMAB, ROMIPLOSTIM, ROMOSOZUMAB-AQQG.
There are a combined 4,228 reports of therapy non responder across 4 Amgen Inc drug(s) in the FDA adverse event database.